News

Senator Durbin, SIU Medicine leaders express concerns about federal budget cuts

Health care leaders and Senator Dick Durbin gathered at SIU School of Medicine on July 25 to strongly denounce sweeping federal budget cuts to Medicaid, student loan support and medical research—pillars that sustain both local patient care and the next generation of physicians.
News

Senator Durbin, SIU Medicine leaders express concerns about federal budget cuts

Health care leaders and Senator Dick Durbin gathered at SIU School of Medicine on July 25 to strongly denounce sweeping federal budget cuts to Medicaid, student loan support and medical research—pillars that sustain both local patient care and the next generation of physicians.
News

Senator Durbin, SIU Medicine leaders express concerns about federal budget cuts

Health care leaders and Senator Dick Durbin gathered at SIU School of Medicine on July 25 to strongly denounce sweeping federal budget cuts to Medicaid, student loan support and medical research—pillars that sustain both local patient care and the next generation of physicians.
News

Senator Durbin, SIU Medicine leaders express concerns about federal budget cuts

Health care leaders and Senator Dick Durbin gathered at SIU School of Medicine on July 25 to strongly denounce sweeping federal budget cuts to Medicaid, student loan support and medical research—pillars that sustain both local patient care and the next generation of physicians.
General Results

Welcome to the MBBS Graduate Program Recruitment Toolkit

SIU School of Medicine’s MBBS Graduate Program offers flexible master’s and doctoral degree options designed to support a wide range of career goals in science, education and health care. Students benefit from interdisciplinary lab rotations, customizable coursework and faculty mentorship across three SIU campuses—Carbondale, Edwardsville and Springfield—giving them the freedom to explore and focus their research interests.
News

Science, scrutiny and staying power: Dr. Sophia Ran’s two decades of cancer research

The rules of scientific research have changed dramatically over the past two decades. Grants are more competitive. Expectations for rigor, repeatability and transparency are higher. And researchers must now juggle cutting-edge methods with rising regulatory demands while pushing for breakthroughs. Quietly yet influentially, Dr. Sophia Ran has met those challenges head-on. Since arriving at SIU School of Medicine in 2003, Ran, has maintained continuous funding from the National Institutes of Health (NIH), the Department of Defense and other agencies, a rare feat even among seasoned
News

Science, scrutiny and staying power: Dr. Sophia Ran’s two decades of cancer research

The rules of scientific research have changed dramatically over the past two decades. Grants are more competitive. Expectations for rigor, repeatability and transparency are higher. And researchers must now juggle cutting-edge methods with rising regulatory demands while pushing for breakthroughs. Quietly yet influentially, Dr. Sophia Ran has met those challenges head-on. Since arriving at SIU School of Medicine in 2003, Ran, has maintained continuous funding from the National Institutes of Health (NIH), the Department of Defense and other agencies, a rare feat even among seasoned
News

Science, scrutiny and staying power: Dr. Sophia Ran’s two decades of cancer research

The rules of scientific research have changed dramatically over the past two decades. Grants are more competitive. Expectations for rigor, repeatability and transparency are higher. And researchers must now juggle cutting-edge methods with rising regulatory demands while pushing for breakthroughs. Quietly yet influentially, Dr. Sophia Ran has met those challenges head-on. Since arriving at SIU School of Medicine in 2003, Ran, has maintained continuous funding from the National Institutes of Health (NIH), the Department of Defense and other agencies, a rare feat even among seasoned
Trial
Psychiatry

ITI-007-321: An Open-label, Multicenter Trial to Assess the Safety and Tolerability of Lumateperone in the Treatment of Pediatric Patients with Schizophrenia, Bipolar Disorder, or Autism Spectrum Disorder

Active recruiting
The primary objective is to evaluate the efficacy of lumateperone administered orally for at least 26 weeks in pediatric patients with schizophrenia (aged 13 to 17 years) or pediatric patients with bipolar disorder (aged 10 to 17 years), or pediatric patients with irritability associated with autism spectrum disorder (ASD) (aged 5 to 17 years).
News

A heart for the mission, a mind for the work: Iris Wesley’s vision broadens care in Illinois

Over more than 40 years at SIU Medicine, Iris Wesley played a key role in expanding access to care across Illinois. Her collaborative leadership helped guide the growth of SIU’s Federally Qualified Health Center network, now one of the largest university-affiliated systems in the country.
Subscribe to Research